Q2 2025 Pharming Group NV Earnings Call Transcript
Key Points
- Pharming Group (PHGUF) reported a 26% increase in total revenues for Q2 2025 compared to the same quarter last year.
- The company achieved an operating profit of $12.9 million, a significant improvement from a loss in the previous year.
- RUCONEST® showed strong performance with a 28% revenue growth, driven by an increase in prescribers and patient enrollments.
- Joenja® experienced a 15% quarter-on-quarter revenue growth, with a notable increase in patients on paid therapy.
- Pharming Group (PHGUF) raised its 2025 total revenue guidance to between $335 million and $350 million, reflecting confidence in continued growth.
- The company faced $2 million in non-recurring expenses related to the Abliva acquisition, impacting overall financials.
- There is a cautious outlook on the reclassification of VUS patients to APDS, with potential delays in realizing the full opportunity.
- Joenja® revenues in the first half of 2025 were slightly down compared to the last half of 2024, attributed to inventory management issues.
- The company anticipates a slight increase in total operating expenses for 2025 due to currency exchange rate impacts.
- Pharming Group (PHGUF) is still in the process of recruiting a new CFO, which may affect financial leadership stability.
Good day and thank you for standing by. Welcome to the Pharming Q2 and First half 2025 financial results conference call and webcast.
(Operator Instruction) I would now like to hand the conference over to your speaker today, Fabrice Chouraqui. Please go ahead.
Thank you, operator, and good morning or good afternoon, everyone, and welcome to our Q2 2025 earning call. So, I'm Fabrice Chouraqui, the CEO of Pharming, and I'll be joined on this call today by Stephen Toor, our Chief Commercial Officer, and Anurag Relan, our Chief Medical Officer.
Next slide.
So, on this call, we will be making forward-looking statements that are based upon our current insights and plans. As this may differ from future results.
Next slide.
So, as you saw in our press release earlier today, Pharming delivered a very strong quarter. Total revenues grew by 26% in the second quarter of 2025 as to the same quarter last year.
And we delivered
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
